金沙检测线路js95(中国)股份有限公司-Official website

You are about to leave Peijia Medical's official Chinese website.

You have just clicked on a link to another website. After clicking Continue, you may be taken to a website run by a third party. We are not responsible for the review and control of content outside Peijia Medical's official Chinese website, nor do we assume any responsibility for business transactions or matters conducted outside Peijia Medical's official Chinese website. The use of other websites is subject to the terms of use and privacy policies of those websites. Certain products or information found on other websites may not be approved for your region or country.

Cancel

Continue

Company News Brief News on Innovation

Peijia Medical Announced Proposed Share Repurchase in the Open Market

2024-06-21 11:30:42

On June 20, Peijia Medical announced that the Board resolved to repurchase shares of the Company in the open market from time to time subject to market conditions, pursuant to the share repurchase mandate approved by the shareholders of the Company at the annual general meeting held on May 25, 2023 (the “2022 AGM”) (the “Share Repurchase Mandate”). Pursuant to the Share Repurchase Mandate, the Company is allowed to repurchase up to 10% of the aggregate number of shares in issue as at the 2022 AGM, i.e. up to 67,885,680 shares.

Prev：Peijia Medical Announced Audited 2023 Annual Results and Resumption of Trading

Next：PEIJIA MEDICAL'S LICENSING PARTNER, JENAVALVE TECHNOLOGY, INC., IS ACQUIRED BY EDWARDS LIFESCIENCES, MARKING A NEW CHAPTER IN THE TRANSCATHETER TREATMENT OF AORTIC REGURGITATION